-
Je něco špatně v tomto záznamu ?
Monoclonal gammopathy of renal significance (MGRS): Real-world data on outcomes and prognostic factors
A. Gozzetti, A. Guarnieri, E. Zamagni, E. Zakharova, D. Coriu, M. Bittrich, T. Pika, N. Tovar, N. Schutz, S. Ciofini, C. Peña, S. Rocchi, M. Rassner, I. Avivi, A. Waszczuk-Gajda, S. Chhabra, L. Usnarska-Zubkiewicz, V. González-Calle, MV. Mateos,...
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, multicentrická studie
NLK
Free Medical Journals
od 1998 do Před 1 rokem
Wiley Free Content
od 1996 do Před 1 rokem
PubMed
35389534
DOI
10.1002/ajh.26566
Knihovny.cz E-zdroje
- MeSH
- autologní transplantace škodlivé účinky MeSH
- dospělí MeSH
- lidé MeSH
- monoklonální gamapatie nejasného významu * komplikace diagnóza terapie MeSH
- nemoci ledvin * etiologie patologie terapie MeSH
- paraproteinemie * diagnóza MeSH
- prekancerózy * MeSH
- prognóza MeSH
- retrospektivní studie MeSH
- senioři MeSH
- transplantace hematopoetických kmenových buněk * škodlivé účinky MeSH
- Check Tag
- dospělí MeSH
- lidé MeSH
- senioři MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
Monoclonal gammopathy of renal significance (MGRS) is a recognized clinical entity. Literature regarding treatment and its outcomes in MGRS is sparse due to the rarity and misdiagnosis of MGRS. We retrospectively analyzed 280 adults with an MGRS diagnosis from 2003 to 2020 across 19 clinical centers from 12 countries. All cases required renal biopsy for the pathological diagnosis of MGRS. Amyloidosis-related to MGRS (MGRS-A) was present in 180 patients; nonamyloidosis MGRS (MGRS-NA), including a broad spectrum of renal pathologies, was diagnosed in 100 patients. The median overall survival in the studied cohort was 121.0 months (95% CI: 105.0-121.0). Patients with MGRS-A had a shorter overall survival than patients with MGRS-NA (HR = 0.41, 95%CI: 0.25-0.69; p = 0.0007). Both hematologic and renal responses were associated with longer survival. Achievement of ≥VGPR was generally predictive of a renal response (OR = 8.03 95%CI: 4.04-115.96; p < 0.0001), one-fourth of patients with ≥VGPR were renal nonresponders. In MGRS-A, factors associated with poor prognosis included elevated levels of creatinine, beta-2-microglobulin, and hemodialysis at diagnosis. In MGRS-NA, only age >65 years was associated with increased risk of death. Treatments provided similar hematologic response rates in both types of MGRS. Autologous stem cell transplantation led to better response than other treatments. This multicenter and international effort is currently the largest report on MGRS.
Department of Hemato Oncology University Hospital Olomouc Olomouc Czech Republic
Department of Hematology Complejo Asistencial de Avila Avila Spain
Department of Hematology Hospital del Salvador Santiago Chile
Department of Hematology Medical Faculty University of Warmia and Mazury in Olsztyn Olsztyn Poland
Department of Internal Medicine 2 University Hospital Würzburg Würzburg Germany
Department of Medicine Division of Nephrology Medical College of Wisconsin Milwaukee Wisconsin USA
Department of Nephrology Moscow City Hospital named after S P Botkin Moscow Russian Federation
Faculty of Medicine Department of Medicine 1 Medical Center University of Freiburg Freiburg Germany
Federal University of Bahia University Hospital Rede D'or Oncology Sao Paolo Brazil
Hematology Department of Medical Science Surgery and Neuroscience University of Siena Siena Italy
Hematology Unit Department of Onco Hematology Cosenza Italy
Instituto de Investigación Biomédica de Salamanca University Hospital of Salamanca Salamanca Spain
IRCCS Azienda Ospedaliero Universitaria di Bologna Istituto di Ematologia Seràgnoli Bologna Italy
Nephrology Azienda Ospedaliera Universitaria Senese Siena Italy
The John Theurer Cancer Center at Hackensack Meridian School of Medicine Hackensack New Jersey USA
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22017844
- 003
- CZ-PrNML
- 005
- 20220804134421.0
- 007
- ta
- 008
- 220720s2022 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1002/ajh.26566 $2 doi
- 035 __
- $a (PubMed)35389534
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Gozzetti, Alessandro $u Hematology, Department of Medical Science, Surgery and Neuroscience, University of Siena, Siena, Italy $1 https://orcid.org/0000000307696891
- 245 10
- $a Monoclonal gammopathy of renal significance (MGRS): Real-world data on outcomes and prognostic factors / $c A. Gozzetti, A. Guarnieri, E. Zamagni, E. Zakharova, D. Coriu, M. Bittrich, T. Pika, N. Tovar, N. Schutz, S. Ciofini, C. Peña, S. Rocchi, M. Rassner, I. Avivi, A. Waszczuk-Gajda, S. Chhabra, L. Usnarska-Zubkiewicz, V. González-Calle, MV. Mateos, M. Bocchia, F. Bigi, H. Füllgraf, B. Bhasin-Chhabra, M. Gentile, J. Davila, DH. Vesole, M. Cavo, B. Thapa, E. Crusoe, H. Einsele, W. Legiec, G. Charliński, A. Jurczyszyn
- 520 9_
- $a Monoclonal gammopathy of renal significance (MGRS) is a recognized clinical entity. Literature regarding treatment and its outcomes in MGRS is sparse due to the rarity and misdiagnosis of MGRS. We retrospectively analyzed 280 adults with an MGRS diagnosis from 2003 to 2020 across 19 clinical centers from 12 countries. All cases required renal biopsy for the pathological diagnosis of MGRS. Amyloidosis-related to MGRS (MGRS-A) was present in 180 patients; nonamyloidosis MGRS (MGRS-NA), including a broad spectrum of renal pathologies, was diagnosed in 100 patients. The median overall survival in the studied cohort was 121.0 months (95% CI: 105.0-121.0). Patients with MGRS-A had a shorter overall survival than patients with MGRS-NA (HR = 0.41, 95%CI: 0.25-0.69; p = 0.0007). Both hematologic and renal responses were associated with longer survival. Achievement of ≥VGPR was generally predictive of a renal response (OR = 8.03 95%CI: 4.04-115.96; p < 0.0001), one-fourth of patients with ≥VGPR were renal nonresponders. In MGRS-A, factors associated with poor prognosis included elevated levels of creatinine, beta-2-microglobulin, and hemodialysis at diagnosis. In MGRS-NA, only age >65 years was associated with increased risk of death. Treatments provided similar hematologic response rates in both types of MGRS. Autologous stem cell transplantation led to better response than other treatments. This multicenter and international effort is currently the largest report on MGRS.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 12
- $a transplantace hematopoetických kmenových buněk $x škodlivé účinky $7 D018380
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a nemoci ledvin $x etiologie $x patologie $x terapie $7 D007674
- 650 12
- $a monoklonální gamapatie nejasného významu $x komplikace $x diagnóza $x terapie $7 D008998
- 650 12
- $a paraproteinemie $x diagnóza $7 D010265
- 650 12
- $a prekancerózy $7 D011230
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a autologní transplantace $x škodlivé účinky $7 D014182
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 700 1_
- $a Guarnieri, Andrea $u Nephrology, Azienda Ospedaliera Universitaria Senese, Siena, Italy
- 700 1_
- $a Zamagni, Elena $u IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy $u Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale Università di Bologna, Bologna, Italy
- 700 1_
- $a Zakharova, Elena $u Department of Nephrology, Moscow City Hospital named after S.P. Botkin, Moscow, Russian Federation
- 700 1_
- $a Coriu, Daniel $u Department of Hematology, Fundeni Clinical Institute, University of Medicine and Pharmacy "Carol Davila", Bucharest, Romania
- 700 1_
- $a Bittrich, Max $u Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany
- 700 1_
- $a Pika, Tomáš $u Department of Hemato-Oncology, University Hospital Olomouc, Olomouc, Czech Republic
- 700 1_
- $a Tovar, Natalia $u Amyloidosis and Myeloma Unit, Department of Hematology, Hospital Clínic of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
- 700 1_
- $a Schutz, Natalia $u Department of Hematology, Hospital del Salvador, Santiago, Chile
- 700 1_
- $a Ciofini, Sara $u Hematology, Department of Medical Science, Surgery and Neuroscience, University of Siena, Siena, Italy
- 700 1_
- $a Peña, Camila $u Department of Hematology, Hospital del Salvador, Santiago, Chile
- 700 1_
- $a Rocchi, Serena $u IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy $u Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale Università di Bologna, Bologna, Italy
- 700 1_
- $a Rassner, Michael $u Faculty of Medicine, Department of Medicine I, Medical Center, University of Freiburg, Freiburg, Germany
- 700 1_
- $a Avivi, Irit $u Tel Aviv Medical Center, Tel Aviv, Israel and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel $1 https://orcid.org/000000018663444X
- 700 1_
- $a Waszczuk-Gajda, Anna $u Departament od Hematology, Transplantology and Internal Medicine, Medical University of Warsaw, Warsaw, Poland $1 https://orcid.org/0000000156261750
- 700 1_
- $a Chhabra, Saurabh $u Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA $1 https://orcid.org/0000000191178696
- 700 1_
- $a Usnarska-Zubkiewicz, Lidia $u Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland
- 700 1_
- $a González-Calle, Verónica $u Instituto de Investigación Biomédica de Salamanca (IBSAL), University Hospital of Salamanca, Salamanca, Spain
- 700 1_
- $a Mateos, Maria-Victoria $u Instituto de Investigación Biomédica de Salamanca (IBSAL), University Hospital of Salamanca, Salamanca, Spain
- 700 1_
- $a Bocchia, Monica $u Hematology, Department of Medical Science, Surgery and Neuroscience, University of Siena, Siena, Italy $1 https://orcid.org/0000000335383913
- 700 1_
- $a Bigi, Flavia $u IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy
- 700 1_
- $a Füllgraf, Hannah $u Department of Hematology, Hospital del Salvador, Santiago, Chile
- 700 1_
- $a Bhasin-Chhabra, Bhavna $u Department of Medicine, Division of Nephrology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA $1 https://orcid.org/0000000311997822
- 700 1_
- $a Gentile, Massimo $u Hematology Unit, Department of Onco-Hematology, Cosenza, Italy
- 700 1_
- $a Davila, Julio $u Department of Hematology, Complejo Asistencial de Avila, Avila, Spain $1 https://orcid.org/0000000251852073
- 700 1_
- $a Vesole, David H $u The John Theurer Cancer Center at Hackensack Meridian School of Medicine, Hackensack, New Jersey, USA
- 700 1_
- $a Cavo, Michele $u IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy $u Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale Università di Bologna, Bologna, Italy
- 700 1_
- $a Thapa, Bicky $u Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
- 700 1_
- $a Crusoe, Edvan $u Federal University of Bahia, University Hospital, Rede D'or Oncology, Sao Paolo, Brazil
- 700 1_
- $a Einsele, Hermann $u Department of Hematology, Fundeni Clinical Institute, University of Medicine and Pharmacy "Carol Davila", Bucharest, Romania
- 700 1_
- $a Legiec, Wojciech $u Department of Hematology and Bone Marrow Transplantation, St. John of Dukla Oncology Center of Lublin Land, Lublin, Poland
- 700 1_
- $a Charliński, Grzegorz $u Department of Hematology, Medical Faculty, University of Warmia and Mazury in Olsztyn, Olsztyn, Poland
- 700 1_
- $a Jurczyszyn, Artur $u Plasma Cell Dyscrasias Center, Department of Hematology, Jagiellonian University Medical College, Faculty of Medicine, Cracow, Poland $1 https://orcid.org/0000000197968365
- 773 0_
- $w MED00000251 $t American journal of hematology $x 1096-8652 $g Roč. 97, č. 7 (2022), s. 877-884
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35389534 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220720 $b ABA008
- 991 __
- $a 20220804134414 $b ABA008
- 999 __
- $a ok $b bmc $g 1821772 $s 1169087
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 97 $c 7 $d 877-884 $e 20220420 $i 1096-8652 $m American journal of hematology $n Am J Hematol $x MED00000251
- LZP __
- $a Pubmed-20220720
